MannKind Corporation Reports 2013 Second Quarter Financial Results
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter ended June 30, 2013.
For the second quarter of 2013, total operating expenses were $41.6 million, compared to $44.1 million for the second quarter of 2012, a decrease of $2.5 million. Research and development (R&D) expenses were $27.1 million for the second quarter of 2013 compared to $26.6 million for the same quarter in 2012, an increase of $0.5 million primarily due to an increase in non-cash stock compensation expense partially offset by a decrease in clinical trial related expenses.
Help employers find you! Check out all the jobs and post your resume.
MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter ended June 30, 2013.
For the second quarter of 2013, total operating expenses were $41.6 million, compared to $44.1 million for the second quarter of 2012, a decrease of $2.5 million. Research and development (R&D) expenses were $27.1 million for the second quarter of 2013 compared to $26.6 million for the same quarter in 2012, an increase of $0.5 million primarily due to an increase in non-cash stock compensation expense partially offset by a decrease in clinical trial related expenses.
Help employers find you! Check out all the jobs and post your resume.